Copyright
©The Author(s) 2025.
World J Gastrointest Surg. Jun 27, 2025; 17(6): 106361
Published online Jun 27, 2025. doi: 10.4240/wjgs.v17.i6.106361
Published online Jun 27, 2025. doi: 10.4240/wjgs.v17.i6.106361
Table 3 Pathological evaluation of response in group immune checkpoint inhibitor and group non-immune checkpoint inhibitor, n (%)
Variable | Group ICI (n = 53) | Group non-ICI (n = 29) | P value |
pCR | 7 (13.2) | 0 (0.0) | 0.048 |
MPR | 19 (35.8) | 4 (13.8) | 0.041 |
ypT0 | 8 (15.1) | 0 (0.0) | 0.046 |
ypN0 | 25 (47.2) | 10 (34.5) | 0.267 |
TRG1a | 7 (13.2) | 0 (0.0) | 0.030 |
TRG1b | 12 (22.6) | 4 (13.8) | - |
TRG2 | 23 (43.4) | 14 (48.3) | - |
TRG3 | 11 (20.8) | 11 (39.7) | - |
- Citation: Chen QX, Zhang YB, Zeng WM, Cai YC, Lv CB, Lian MQ, Huang RJ, Lian MJ, Lian WL, Xu QH, Sun YQ, Cai LS. Efficacy and safety of sintilimab combined with nab-paclitaxel plus S-1 for neoadjuvant treatment of locally advanced gastric cancer. World J Gastrointest Surg 2025; 17(6): 106361
- URL: https://www.wjgnet.com/1948-9366/full/v17/i6/106361.htm
- DOI: https://dx.doi.org/10.4240/wjgs.v17.i6.106361